The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim

Journal of Clinical Investigation

Volumn 111, Issue 12, 2003, Pages 1897-1904

  Chen, Chun Rong ^a   Pichurin, Pavel ^a   Nagayama, Yuji ^b   Latrofa, Francesco ^a   Rapoport, Basil ^a   McLachlan, Sandra M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AUTOANTIBODY; AUTOANTIGEN; RECEPTOR SUBUNIT; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR A SUBUNIT; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; PROTEIN SUBUNIT;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CHEMICAL STRUCTURE; DISULFIDE BOND; DNA MODIFICATION; FEMALE; GENE EXPRESSION; GOITER; GRAVES DISEASE; HYPERTHYROIDISM; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROTOXICOSIS; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MUTAGENESIS; PATHOLOGY; THYROID GLAND;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, BLOCKING; AUTOANTIBODIES; AUTOANTIGENS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; GRAVES DISEASE; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MUTAGENESIS; PROTEIN SUBUNITS; RECEPTORS, THYROTROPIN; THYROID GLAND;

EID: 0042744788     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317069     Document Type: Article

References (42)

1. Vanderpump, M.P.J., et al. 1995. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.). 43:55-68.
2. Rapoport, B., Chazenbalk, G.D., Jaume, J.C., and McLachlan, S.M. 1998. The thyrotropin receptor: interaction with thyrotropin and autoantibodies. Endocr. Rev. 19:673-716.
3. Tomer, Y., Barbesino, G., Greenberg, D.A., Concepcion, E., and Davies, T.F. 1999. Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. J. Clin. Endocrinol. Metab. 84:4656-4664.
4. Brix, T.H., Kyvik, K.O., Christensen, K., and Hegedus, L. 2001. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 86:930-934.
5. Buckland, P.R., Rickards, C.R., Howells, R.D., Jones, E.D., and Rees Smith, B. 1982. Photo-affinity labeling of the thyrotropin receptor. FEBS Lett. 145:245-249.
6. Loosfelt, H., et al. 1992. Two-subunit structure of the human thyrotropin receptor. Proc. Natl. Acad. Sci. U. S. A. 89:3765-3769.
7. Couet, J., et al. 1996. Shedding of human thyrotropin receptor ectodomain: involvement of a matrix metalloprotease. J. Biol. Chem. 271:4545-4552.
8. Tanaka, K., Chazenbalk, G.D., McLachlan, S.M., and Rapoport, B. 1999. The shed component of the TSH receptor is primarily a carboxyl terminal truncated form of the A subunit, not the entire A subunit. Mol. Cell Endocrinol. 150:113-119.
9. Chazenbalk, G.D., et al. 2002. Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J. Clin. Invest. 110:209-217. doi:10.1172/JCI200215745.
10. Shimojo, N., et al. 1996. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc. Natl. Acad. Sci. U. S. A. 93:11074-11079.
11. Costagliola, S., et al. 2000. Generic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J. Clin. Invest. 105:803-811.
12. Kaithamana, S., Fan, J., Osuga, Y., Liang, S.G., and Prabhakar, B.S. 1999. Induction of experimental autoimmune Graves' disease in BALB/c mice. J. Immunol. 163:5157-5164.
13. Nagayama, Y., et al. 2002. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol. 168:2789-2794.
14. Chazenbalk, G.D., Jaume, J.C., McLachlan, S.M., and Rapoport, B. 1997. Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. J. Biol. Chem. 272:18959-18965.
15. Tanaka, K., Chazenbalk, G.D., McLachlan, S.M., and Rapoport, B. 1998. Thyrotropin receptor cleavage at site 1 does not involve a specific amino acid motif but instead depends on the presence of the unique, 50 amino acid insertion. J. Biol. Chem. 273:1959-1963.
16. Mizuguchi, H., and Kay, M.A. 1998. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9:2577-2583.
17. Mizuguchi, H., and Kay, M.A. 1999. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10:2013-2017.
18. Mittereder, N., March, K.L., and Trapnell, B.C. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509.
19. Pichurin, P., et al. 2001. Naked thyrotropin receptor DNA vaccination: a TH1 T cell response in which interferon-γ production, rather than antibody, dominates the immune response in mice. Endocrinology. 142:3530-3536.
20. Chazenbalk, G.D., et al. 1999. A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies. J. Clin. Endocrinol. Metab. 84:702-710.
21. Kita, M., et al. 1999. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Endocrinology. 140:1392-1398.
22. Pichurin, P., et al. 2002. Immune deviation away from Th1 in interferon-gamma knock-out mice does not enhance TSH receptor antibody production after naked DNA vaccination. Endocrinology. 143:1182-1189.
23. Kakinuma, A., Chazenbalk, G., Filetti, S., McLachlan, S.M., and Rapoport, B. 1996. Both the 5′ and 3′ non-coding regions of the thyrotropin receptor messenger RNA influence the level of receptor protein expression in transfected mammalian cells. Endocrinology. 137:2664-2669.
24. Smith, B.R. 1970. The interaction of the long-acting thyroid stimulator (LATS) with thyroid tissue in vitro. J. Endocrinol. 46:45-54.
25. Foti, D., Russo, D., Costante, G., and Filetti, S. 1991. The biological activity of bovine and human thyrotropin is differently affected by trypsin treatment of human thyroid cells: thyroid-stimulating antibody is related to human thyrotropin. J. Clin. Endocrinol. Metab. 73:710-716.
26. Misrahi, M., and Milgrom, E. 1997. Cleavage and shedding of the TSH receptor. Eur. J. Endocrinol. 137:599-602.
27. Chazenbalk, G.D., Pichurin, P., McLachlan, S.M., and Rapoport, B. 1999. A direct binding assay for thyrotropin receptor autoantibodies. Thyroid. 9:1057-1061.
28. Sanders, J., et al. 1999. The interaction of TSH receptor autoantibodies with 125I-labeled TSH receptor. J. Clin. Endocrinol. Metab. 84:3797-3802.
29. Minich, W.B., and Loos, U. 1999. Isolation of radiochemically pure 125I-labeled human thyrotropin receptor and its use for the detection of pathological autoantibodies in sera from Graves' patients. J. Endocrinol. 160:239-245.
30. Sanders, J., et al. 2002. Thyroid stimulating monoclonal antibodies. Thyroid. 12:1043-1050.
31. Ando, T., Imaizumi, M., Graves, P., Unger, P., and Davies, T.F. 2003. Induction of thyroid-stimulating hormone receptor autoimmunity in hamsters. Endocrinology. 144:671-680.
32. Costagliola, S., et al. 2002. Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. Biochem. Biophys. Res. Commun. 299:891-896.
33. Kraiem, Z., Baron, E., Kahana, L., Sadeh, O., and Sheinfeld, M. 1992. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism. Clin. Endocrinol. (Oxf). 36:211-214.
34. Kasagi, K., et al. 1993. Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: a case report. Thyroid. 3:315-318.
35. Zakarija, M., McKenzie, J.M., and Munro, D.S. 1983. Immunoglobulin G inhibitor of thyroid-stimulating antibody is a cause of delay in the onset of neonaral Graves' disease. J. Clin. Invest. 72:1352-1356.
36. Casiano, C.A., Martin, S.J., Green, D.R., and Tan, E.M. 1996. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J. Exp. Med. 184:765-770.
37. Saegusa, K., et al. 2002. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren's syndrome. J. Immunol. 169:1050-1057.
38. Hammond, L.J., et al. 1997. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J. Pathol. 182:138-144.
39. Salmaso, C., et al. 2002. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves' disease. Ann. N. Y. Acad. Sci. 966:496-501.
40. Couet, J., et al. 1996. Cell surface protein disulfide-isomerase is involved in the shedding of human thyrotropin receptor ectodomain. Biochemistry. 35:14800-14805.
41. Ghinea, N., Baratti-Elbaz, C., Jesus-Lucas, A., and Milgrom, E. 2002. TSH receptor interaction with the extracellular matrix: role on constitutive activity and sensitivity to hormonal stimulation. Mol. Endocrinol. 16:912-923.
42. Linehan, S.A., Martinez-Pomares, L., da Silva, R.P., and Gordon, S. 2001. Endogenous ligands of carbohydrate recognition domains of the mannose receptor in murine macrophages, endothelial cells and secretory cells; potential relevance to inflammation and immunity. Eur. J. Immunol. 31:1857-1866.